Subcutaneous drug administration has shown to be a feasible and promising alternative to intravenous administration. The accelerated production of biologics is responsible for the increasing need for subcutaneous drug delivery. Furthermore, the subcutaneous route of administration is widely favored because it allows patients to self-medicate, increases quality of life, and lowers healthcare costs.
Furthermore, the ease and protection that subcutaneous instruments provide for both patients and medical professionals are key factors driving the global subcutaneous drug delivery industry forward. About 2 million healthcare workers worldwide contracted infectious diseases as a result of needle stick attacks in 2014, according to the World Health Organization. The retractable design of prefilled syringes aids in overcoming this problem, making them an excellent device for reducing needlestick injuries.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2933
In 2020, the global subcutaneous drug delivery market is projected to be worth US$ 9,111.6 million, with a CAGR of 9.7% over the forecast period (2020-2027).
Increasing adoption of inorganic growth strategies by key players is projected to drive market growth over the forecast period:
The market is expected to expand due to manufacturers’ increasing emphasis on inorganic growth strategies such as alliance and alliance in order to improve their product portfolio of subcutaneous drug delivery systems. For example, In October 2017, EVER Neuro Pharma GmbH purchased PHARMAGEN CZ s.r.o, a firm that specializes in injectable located in Slovakia, Europe.
EVER extended its business reach in Europe and leveraged its niche injectable portfolio with this acquisition.
To support the global subcutaneous drug delivery industry expansion, more emphasis is being placed on preventing needlestick injuries:
Injection needle and lancing system needlestick complications are a major problem for diabetic patients. Insulin syringe needlestick accidents are a type of percutaneous wound injury incurred by the needle tips, which can happen when using, treating, disassembling, or disposing of needles and syringes. Key factors driving growth include increased safety consciousness and anxiety over needlestick accidents of the subcutaneous drug delivery market.
Protection injection systems are becoming more common with healthcare practitioners and suppliers, as they reduce the risk of needlestick accidents. To avoid needlestick accidents, the WHO recommends the use of safety syringes with sharp injury resistance (SIP). Furthermore, in May 2017, Innovative Neurons LLC revealed its plan to commercialize Quick (fast, affordable, secure, and technology), a proprietary auto-retractable multi-needle syringe designed to reduce needlestick accidents. The ‘SafeTouch’ protective needle was introduced by Nipro Medical Corporation in 2016, and it prevents patients from needlestick accidents.
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2933
The inaccessibility of approved products because of expanding number of product reviews by different developers is a factor hindering development of the worldwide subcutaneous drug delivery market. For example, on May 18, 2020, Bausch and Lomb UK Limited reported a review of Emerade 500 microgram auto-injectors, attributable to blunder in one part of auto injector, which made the disappointment actuate the pen and deliver adrenaline drug. In addition, in April 2018, Becton Dickson and Company declared review of PosiFlush Heaparin Lock Flush Syringe and Prefilled ordinary saline needle, attributable to pollution with Serratia marcescens bacterium.
In March 2017, Mylan N.V. and its EpiPen Auto-injector production company voluntarily recalled EpiPen and EpiPen Jr auto-injectors sold in the United States, as well as markets in Europe, Asia, North, and South America, after consulting with the US Food and Drug Administration (FDA). The recall was prompted by the device’s inability to work in an emergency due to a possible defecation.
Impact of Coronavirus (Covid-19) Pandemic:
COVID-19 has spread to over 100 countries worldwide since its occurrence in December 2019, prompting the World Health Organization to declare it a public health emergency. According to a survey by the World Health Organization, coronavirus (COVID-19) has infected more than 5 million people worldwide as of June 2020.
COVID-19 has the potential to change the economy in three ways: actively disrupting supply and consumption, causing sales chain delays, and having a financial impact on businesses and financial markets. This has devastated supply chains and industrial operations in India, China, and the United States, while several other nations, including Egypt, United Arab Emirates and Saudi Arabia and others, are still operating normally facing problems with regards to transportation of drugs from one place to another.
Because of the lockdown, there could be a surge in demand for such drugs due to stockpiling of subcutaneous or oral formulations. Manufacturers with manufacturing facilities in Austria, Europe, such as Novartis AG, are especially at risk on the supply side, according to an article published in the Center for Biosimilars (American Journal of Managed Care) on February 27, 2020.
As a result, the global subcutaneous drug delivery market is predicted to be constrained by the effects of the coronavirus (COVID-19) pandemic during the forecast period.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/subcutaneous-drug-delivery-market-to-surpass-us-158-billion-by-2026-1763
The expansion of the North American subcutaneous drug delivery market is being fueled by companies’ efforts to make autoinjectors available to patients suffering from anaphylaxis and other diseases. For example, Mylan N.V. sells epinephrine customers discount cards with discounts of up to US$ 300 on the advertised EpiPen and up to US$ 25 off the licenced generic form of EpiPen. Manufacturers are concentrating their efforts on resolving the region’s commodity scarcity issue. For example, Kaleo confirmed adequate availability of AUVI-Q for anaphylaxis treatment in August 2018.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027